ArticleBiomolecules2026
Construction of an Esophageal Cancer Prognostic Model Based on Mitochondrial Energy Metabolism-Related Genes and Mechanism of INHBA in Promoting Malignant Progression via the Smad2/3 Pathway.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveEsophageal cancer (ESCA) has poor prognosis and lacks reliable biomarkers. This study aimed to construct a mitochondrial energy metabolism-related prognostic model and identify key regulatory genes.
methodsTCGA-ESCA and GSE53625 data were used as training and validation cohorts, respectively. Mitochondrial energy metabolism scores were calculated by ssGSEA. Differential expression analysis and WGCNA identified key genes, followed by consensus clustering, Cox/LASSO regression, enrichment analysis, immune infiltration, TIDE evaluation, and nomogram development. INHBA knockdown or overexpression was performed in KYSE-150 and TE-1 cells to assess malignant phenotypes, mitochondrial function, EMT markers, and Smad2/3 signaling, with SB431542 used for pathway blockade.
resultsHigh mitochondrial energy metabolism scores predicted poorer overall survival. A total of 124 key genes were identified, and three molecular subtypes were established, with Cluster 2 showing the worst prognosis. A four-gene signature comprising COL11A1, INHBA, TNFAIP6, and POSTN stratified patients into high- and low-risk groups in both cohorts. High-risk tumors were enriched in extracellular matrix remodeling, cell adhesion, inflammatory response, hypoxia, angiogenesis, and PI3K-Akt signaling, whereas oxidative phosphorylation was more active in low-risk tumors. The high-risk group had higher TIDE scores, suggesting poorer immunotherapy response. The nomogram incorporating risk group and M stage showed limited discrimination after bootstrap correction. In vitro, INHBA promoted proliferation, migration, invasion, EMT, mitochondrial membrane potential, ATP production, and oxidative phosphorylation. SB431542 partially reversed these effects.
conclusionsThis MEMRG-based model predicts ESCA prognosis and immune features. INHBA promotes ESCA progression by activating Smad2/3-mediated EMT and mitochondrial metabolic reprogramming, suggesting its potential as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.